Pilot, research, and investor overview
SyncSOAP is a clinical documentation support platform designed to help clinicians generate reviewable draft SOAP notes from encounter information, with an initial focus on dermatology workflows.
Compliance posture
SyncSOAP is designed around a HIPAA-aligned architecture using HIPAA-eligible cloud infrastructure. Live PHI use will remain disabled until appropriate BAAs, access controls, retention policies, and customer agreements are in place.
Current stage
Validation in mock and non-PHI settings, with staged operational gating before any PHI-enabled pilot.
Differentiation
Dermatology-first validation, cost-aware model routing, and faithfulness-first documentation workflow design.
Intended collaborators
Physician collaborators, pilot sites, investors, research partners, and grant reviewers.
Current Validation Stage
The product is being evaluated before live PHI deployment
The near-term goal is careful workflow validation, model benchmarking, and measurement of note quality before broader operational rollout.
Mock-patient study workflow
No live PHI in validation
Model comparison across latency, cost, and clinical faithfulness
Human-reviewed grading of completeness and hallucination risk
Pilot Participation
Who should reach out
We are interested in collaborators who want to help validate documentation workflows in a measured, staged way.
Dermatology clinics
Physicians interested in workflow validation
Medical students and research collaborators
Academic partners
Pilot Stages
A staged path from mock validation to limited production use
The pilot design is intentionally progressive. Each stage is meant to validate workflow safety and operational readiness before the next one opens.
Stage 0: mock-patient validation
Stage 1: non-PHI workflow testing
Stage 2: limited PHI-enabled pilot only after BAAs and approvals
Research Metrics
What we plan to measure
Evaluation is centered on note quality, clinician burden, and operational feasibility rather than marketing-style output claims.
Time to signable note
Completeness
Unsupported additions and hallucinations
Editing burden
Model latency
Cost per note
Clinician usability
Investor View
Why the approach may be differentiated
The strategy is to start with a narrower, testable clinical wedge and build the controls and workflow evidence needed for broader outpatient expansion. We also believe the category direction is being validated by meaningful capital formation around AI documentation tooling, which reinforces that clinician documentation remains a strategically important workflow.
Dermatology-focused starting wedge
Compliance-aware architecture
Model governance layer
Cost-aware model routing
Faithfulness-first documentation
Early research pathway
Category Momentum
Why we believe the market is moving in this direction
We do not view category investment as proof of product-market fit on its own, but we do view it as evidence that clinical documentation, clinician burnout, and workflow automation remain significant areas of strategic focus across healthcare AI.
Abridge announced a $150 million funding round in February 2024 focused on clinical documentation AI.
Suki announced a $70 million funding round in October 2024 to expand its AI assistant and scribe capabilities.
One U.S. market estimate sized AI medical scribing at about $397 million in 2024 and projected growth toward roughly $3.0 billion by 2033.
Expansion Path
Wedge to platform
The product should not be framed as dermatology-only forever or as universally ready across specialties today. The current positioning is focused, deliberate, and scalable.
Phase 1: Dermatology workflows
Phase 2: General outpatient documentation
Phase 3: Specialty-specific workflows
What we're building
Documentation support, not autonomous care
SyncSOAP is designed to support reviewable draft documentation. It is not intended to replace physician judgment, provide autonomous diagnosis, or operate as unattended clinical decision-making software.
Built on HIPAA-eligible infrastructure
The architecture is being shaped to support a BAA-backed deployment pathway, while live PHI remains gated until the required agreements and operational controls are complete.
Contact
Start a conversation
If you are evaluating SyncSOAP for a pilot, investment conversation, partnership, or research collaboration, reach out directly.